Consistently, MARCH2 mRNA levels were significantly lower in patients with SLE than in healthy donors (Figure 8Q), supporting the hypothesis that dysregulated TFEB and MARCH2 contribute to PBLD upregulation in SLE. Here, TFEB is linked to systemic lupus erythematosus.